New Cancer Gene Therapy Study Results Reported from Shandong University (Effects of INPP4B gene transfection combined with PARP inhibitor on castration therapy-Resistant prostate cancer cell line, PC3)
By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Investigators publish new report on Biotechnology. According to news reporting originating in Shandong, People's Republic of China, by NewsRx journalists, research stated, "This study investigated the effects of combining inositol polyphosphate-4-phosphatase type II (INPP4B) gene transfection with poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor on castration therapy-resistant prostate cancer cell line, PC3. PC3 and LNcap cells were cultured in vitro, and the expression of INPP4B at the messenger RNA level was detected using reverse transcription polymerase chain reaction."
The news reporters obtained a quote from the research from Shandong University, "PC3 cells transfected with recombinant lentivirus vector carrying the human INPP4B gene, and the expression of INPP4B was confirmed using real-time polymerase chain reaction and Western blot. The effect of INPP4B transfection or PARP inhibitor treatment or both on the proliferation, apoptosis and cell cycle, and level of protein kinase B (p-AKT) of PC3 cells was determined using Cell Counting Kit-8 assay, flow cytometry, and Western blot, respectively. INPP4B gene was lost in PC3 cells and successfully expressed in PC3 cells after recombinant lentivirus transfection. Cell proliferation was inhibited and the level of p-AKT decreased, causing a G1 arrest. PARP inhibitor had a remarkable negative effect on cell proliferation and promoted apoptosis, conferring a G2/M arrest, which was dose dependent; however, the level of intracellular p-AKT showed a slight rise. INPP4B gene transfection and PARP inhibitor combined blocked cell cycle progression in G1 phase, enhanced the inhibition of cell proliferation, and kept low intracellular p-AKT level."
According to the news reporters, the research concluded: "Our results demonstrated that the combination of INPP4B gene transfection and PARP inhibitor had a synergistic antitumor effect on PC3 cells, which was expected to shed new light on combined biological therapy in castration therapy-resistant prostate cancer."
For more information on this research see: Effects of INPP4B gene transfection combined with PARP inhibitor on castration therapy-Resistant prostate cancer cell line, PC3. Urologic Oncology-Seminars and Original Investigations, 2014;32(5):720-726. Urologic Oncology-Seminars and Original Investigations can be contacted at: Elsevier Science Inc, 360 Park Ave South, New York, NY 10010-1710, USA (see also Biotechnology).
Our news correspondents report that additional information may be obtained by contacting H. Ding, Shandong University, Sch Med, Jinan, Shandong, People's Republic of China. Additional authors for this research include Y. Sun, Y. Hou and L. Li.
Keywords for this news article include: Shandong, People's Republic of China, Asia, Biotechnology, Cancer Gene Therapy, Cell Line, Cell Proliferation, Cultured Cells, Diagnosis, Diagnostics, Enzymes and Coenzymes, Lentivirus, Oncology, Polymerase, Prostate Cancer, Prostatic Neoplasms, RNA Viruses, Retroviridae
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC